Nexalin Technology, Inc.
(NXL)
Add Watchlist
1.31 USD +0.01
Closed: 17 May, 3:55 pm
Symbol NXL
Market Cap 9.7M
Price 1.31
Open 1.34
52-wk High 3.40
50 Day Avg 1.35
Earnings Announcement 2024-05-08
Website https://www.nexalin.com
Name Nexalin Technology, Inc.
Shares Outstanding 7,436,562
Change % -1.5038%
Low 1.29
52-wk Low 0.25
200 Day Avg 0.64
Last Dividend 0.00
Exchange NASDAQ
Volume 5,915
Previous Close 1.33
High 1.38
EPS -0.63
PE -2.08
Avg Volume 836,350
CUSIP 65345B201
Nexalin Technology, Inc. Outlook
Description Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
Currency USD
ISIN US65345B2016
Industry Medical - Devices
Changes -0.02
CUSIP 65345B201
Range 0.25 - 3.40
Beta 5.43
CIK 0001527352

Nexalin Technology, Inc. News

25-Apr-2024 10:44 AM

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

HOUSTON, TEXAS, April 25, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced that the Company received notice from The Nasdaq Stock Market (“Nasdaq”) on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2).

10-Apr-2024 8:30 AM

Nexalin Technology CEO Provides Letter to Shareholders

Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model

04-Apr-2024 1:00 PM

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes

02-Apr-2024 2:41 PM

Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veterans

Nexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury (mTBI). The company said that the study, conducted at the University of California San Diego, achieved a statistically significant decrease in post-concussion symptoms and post-traumatic stress disorder symptoms for patients treated with Nexalin's non-invasive, frequency-based deep brain stimulation device when compared to the control group.

02-Apr-2024 8:30 AM

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Previously served as Acting General Counsel to the Department of Veterans Affairs Previously served as Acting General Counsel to the Department of Veterans Affairs

28-Mar-2024 8:30 AM

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group

14-Mar-2024 8:30 AM

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology

Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder

13-Mar-2024 8:30 AM

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Event hosted by the U.S. Army Medical Research and Development Command's (USAMRDC) Combat Casualty Care Research Program (CCCRP) Neurotrauma Portfolio and the Biomedical Advanced Research and Development Authority (BARDA)

06-Mar-2024 8:30 AM

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Clinical study demonstrated clinically meaningful and statistically significant improvements in key sleep parameters, compared to adult patients treated with placebo Data published in Journal of Psychiatric Research suggests that the Gen-2 tACS device may have the potential to reduce chronic insomnia and consistently improve sleep quality and efficiency in adults Chronic insomnia is often associated with fatigue, mood changes, difficulty concentrating and impaired daytime functioning HOUSTON, TEXAS, March 06, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced positive results of a clinical study of its Gen-2 tACS device (“tACS”) for the treatment of chronic insomnia. This clinical study, conducted at Xuanwu Hospital of Capital Medical University in Beijing and Beijing Anding Hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.

08-Feb-2024 8:30 AM

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Company's International Reach Expanding with Latest Regulatory Approval Company's International Reach Expanding with Latest Regulatory Approval

23-Jan-2024 8:30 AM

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company's non-invasive, frequency-based deep brain stimulation device.  The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System,” covers the core technology utilized in the Company's Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner.